{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:49:00Z","timestamp":1786981740577,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T00:00:00Z","timestamp":1547856000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12951-019-0442-x","type":"journal-article","created":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T08:03:04Z","timestamp":1547884984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Integration of phospholipid-complex nanocarrier assembly with endogenous N-oleoylethanolamine for efficient stroke therapy"],"prefix":"10.1186","volume":"17","author":[{"given":"Xiangrui","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanxi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8511-0281","authenticated-orcid":false,"given":"Shichao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxiong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoshu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,19]]},"reference":[{"key":"442_CR1","unstructured":"Centers for Disease Control and Prevention, National Center for Health Statistics. Underlying Cause of Death 1999\u20132013 on CDC WONDER Online database, released 2015. Data are from the Multiple Cause of Death Files, 1999\u20132013, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program: \n                    http:\/\/wonder.cdc.gov\/ucd-icd10.html\n                    \n                  . Accessed Feb 3 2015."},{"key":"442_CR2","first-page":"421","volume":"58","author":"Centers for Disease Control and Prevention (CDC)","year":"2009","unstructured":"Centers for Disease Control and Prevention (CDC). Prevalence and most common causes of disability among adults: United States, 2005. MMWR Morb Mortal Wkly Rep. 2009;58:421\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"442_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrn1106","volume":"4","author":"EH Lo","year":"2003","unstructured":"Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci. 2003;4:399\u2013415.","journal-title":"Nat Rev Neurosci"},{"key":"442_CR4","doi-asserted-by":"publisher","first-page":"E98","DOI":"10.1161\/STR.0000000000000098","volume":"47","author":"CJ Winstein","year":"2016","unstructured":"Winstein CJ, Stein J, Arena R, Bates B, Cherney LR, Cramer SC, Deruyter F, Eng JJ, Fisher B, Harvey RL, et al. Guidelines for Adult Stroke Rehabilitation and Recovery A Guideline for Healthcare Professionals From the American Heart Association\/American Stroke Association. Stroke. 2016;47:E98\u2013169.","journal-title":"Stroke"},{"key":"442_CR5","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1161\/01.STR.0000025518.34157.51","volume":"33","author":"DJ Gladstone","year":"2002","unstructured":"Gladstone DJ, Black SE, Hakim AM, Heart Stroke Fdn Ontario Ctr E. Toward wisdom from failure\u2014lessons from neuroprotective stroke trials and new therapeutic directions. Stroke. 2002;33:2123\u201336.","journal-title":"Stroke"},{"key":"442_CR6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.clineuro.2009.04.001","volume":"111","author":"R Brouns","year":"2009","unstructured":"Brouns R, De Deyn PP. The complexity of neurobiological processes in acute ischemic stroke. Clin Neurol Neurosurg. 2009;111:483\u201395.","journal-title":"Clin Neurol Neurosurg"},{"key":"442_CR7","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1038\/jcbfm.2011.127","volume":"31","author":"D Vivien","year":"2011","unstructured":"Vivien D, Gauberti M, Montagne A, Defer G, Touz\u00e9 E. Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence. J Cereb Blood Flow Metab. 2011;31:2119\u201334.","journal-title":"J Cereb Blood Flow Metab"},{"key":"442_CR8","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S1474-4422(13)70091-7","volume":"12","author":"MG Hennerici","year":"2013","unstructured":"Hennerici MG, Kern R, Szabo K. Non-pharmacological strategies for the treatment of acute ischaemic stroke. Lancet Neurol. 2013;12:572\u201384.","journal-title":"Lancet Neurol"},{"key":"442_CR9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.neuropharm.2012.03.008","volume":"63","author":"Y Zhou","year":"2012","unstructured":"Zhou Y, Yang L, Ma A, Zhang X, Li W, Yang W, Chen C, Jin X. Orally administered oleoylethanolamide protects mice from focal cerebral ischemic injury by activating peroxisome proliferator-activated receptor alpha. Neuropharmacology. 2012;63:242\u20139.","journal-title":"Neuropharmacology"},{"key":"442_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00210-016-1309-4","volume":"390","author":"H Zhou","year":"2017","unstructured":"Zhou H, Yang W-S, Li Y, Ren T, Peng L, Guo H, Liu J-F, Zhou Y, Zhao Y, Yang L-C, Jin X. Oleoylethanolamide attenuates apoptosis by inhibiting the TLR4\/NF-kappa B and ERK1\/2 signaling pathways in mice with acute ischemic stroke. Naunyn-Schmiedebergs Arch Pharmacol. 2017;390:77\u201384.","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"442_CR11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.bcp.2015.02.012","volume":"94","author":"L-C Yang","year":"2015","unstructured":"Yang L-C, Guo H, Zhou H, Suo D-Q, Li W-J, Zhou Y, Zhao Y, Yang W-S, Jin X. Chronic oleoylethanolamide treatment improves spatial cognitive deficits through enhancing hippocampal neurogenesis after transient focal cerebral ischemia. Biochem Pharmacol. 2015;94:270\u201381.","journal-title":"Biochem Pharmacol"},{"key":"442_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/nbm.1157","volume":"20","author":"JB Pialat","year":"2007","unstructured":"Pialat JB, Cho TH, Beuf O, Joye E, Moucharaffie S, Langlois JB, Nemoz C, Janier M, Berthezene Y, Nighoghossian N, et al. MRI monitoring of focal cerebral ischemia in peroxisome proliferator-activated receptor (PPAR)-deficient mice. NMR Biomed. 2007;20:335\u201342.","journal-title":"NMR Biomed"},{"key":"442_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.neulet.2008.12.045","volume":"451","author":"G Cheng","year":"2009","unstructured":"Cheng G, Zhang X, Gao DK, Jiang XF, Dong WP. Resveratrol inhibits MMP-9 expression by up-regulating PPAR alpha expression in an oxygen glucose deprivation-exposed neuron model. Neurosci Lett. 2009;451:105\u20138.","journal-title":"Neurosci Lett"},{"key":"442_CR14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.freeradbiomed.2006.04.030","volume":"41","author":"M Collino","year":"2006","unstructured":"Collino M, Aragno M, Mastrocola R, Benetti E, Gallicchio M, Dianzani C, Danni O, Thiemermann C, Fantozzi R. Oxidative stress and inflammatory response evoked by transient cerebral ischemia\/reperfusion: effects of the PPAR-alpha agonist WY14643. Free Radical Biol Med. 2006;41:579\u201389.","journal-title":"Free Radical Biol Med"},{"key":"442_CR15","doi-asserted-by":"publisher","first-page":"6264","DOI":"10.1523\/JNEUROSCI.23-15-06264.2003","volume":"23","author":"D Deplanque","year":"2003","unstructured":"Deplanque D, Gele P, Petrault O, Six I, Furman C, Bouly M, Nion S, Dupuis B, Leys D, Fruchart JC, et al. Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci. 2003;23:6264\u201371.","journal-title":"J Neurosci"},{"key":"442_CR16","doi-asserted-by":"publisher","first-page":"27849","DOI":"10.1074\/jbc.M404087200","volume":"279","author":"M Guzman","year":"2004","unstructured":"Guzman M, Lo Verme J, Fu J, Oveisi F, Blazquez C, Piomelli D. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J Biol Chem. 2004;279:27849\u201354.","journal-title":"J Biol Chem"},{"key":"442_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nature01921","volume":"425","author":"J Fu","year":"2003","unstructured":"Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, de Fonseca FR, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G, Piomelli D. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature. 2003;425:90\u20133.","journal-title":"Nature"},{"key":"442_CR18","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.2217\/nnm.14.35","volume":"9","author":"M Wulff-Perez","year":"2014","unstructured":"Wulff-Perez M, Pavon FJ, Martin-Rodriguez A, de Vicente J, Alen F, de Fonseca FR, Galvez-Ruiz MJ, Serrano A. Preparation, characterization and in vivo evaluation of nanoemulsions for the controlled delivery of the antiobesity agent N-oleoylethanolamine. Nanomedicine. 2014;9:2761\u201372.","journal-title":"Nanomedicine"},{"key":"442_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ejps.2007.05.110","volume":"31","author":"S Stegemann","year":"2007","unstructured":"Stegemann S, Leveiller F, Franchi D, de Jong H, Linden H. When poor solubility becomes an issue: from early stage to proof of concept. Eur J Pharm Sci. 2007;31:249\u201361.","journal-title":"Eur J Pharm Sci"},{"key":"442_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1056-8719(00)00107-6","volume":"44","author":"CA Lipinski","year":"2000","unstructured":"Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44:235\u201349.","journal-title":"J Pharmacol Toxicol Methods"},{"key":"442_CR21","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.addr.2007.10.014","volume":"60","author":"CJH Porter","year":"2008","unstructured":"Porter CJH, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev. 2008;60:673\u201391.","journal-title":"Adv Drug Deliv Rev"},{"key":"442_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0168-3659(00)00339-4","volume":"70","author":"KS Soppimath","year":"2001","unstructured":"Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70:1\u201320.","journal-title":"J Control Release"},{"key":"442_CR23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S0169-409X(02)00228-4","volume":"55","author":"J Panyam","year":"2003","unstructured":"Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003;55:329\u201347.","journal-title":"Adv Drug Deliv Rev"},{"key":"442_CR24","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd2614","volume":"7","author":"ME Davis","year":"2008","unstructured":"Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discovery. 2008;7:771\u201382.","journal-title":"Nat Rev Drug Discovery"},{"key":"442_CR25","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/sj.clpt.6100400","volume":"83","author":"L Zhang","year":"2008","unstructured":"Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83:761\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"442_CR26","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/j.addr.2004.02.014","volume":"56","author":"L Brannon-Peppas","year":"2004","unstructured":"Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004;56:1649\u201359.","journal-title":"Adv Drug Deliv Rev"},{"key":"442_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2013.08.008","volume":"71","author":"J Kreuter","year":"2014","unstructured":"Kreuter J. Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? Adv Drug Deliv Rev. 2014;71:2\u201314.","journal-title":"Adv Drug Deliv Rev"},{"key":"442_CR28","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1002\/adfm.201500680","volume":"25","author":"J-Y Lee","year":"2015","unstructured":"Lee J-Y, Chung S-J, Cho H-J, Kim D-D. Phenylboronic acid-decorated chondroitin sulfate a-based theranostic nanoparticles for enhanced tumor targeting and penetration. Adv Func Mater. 2015;25:3705\u201317.","journal-title":"Adv Func Mater"},{"key":"442_CR29","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S0169-409X(02)00044-3","volume":"54","author":"I Brigger","year":"2002","unstructured":"Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002;54:631\u201351.","journal-title":"Adv Drug Deliv Rev"},{"key":"442_CR30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1021\/mp300489p","volume":"10","author":"Z Hou","year":"2013","unstructured":"Hou Z, Li Y, Huang Y, Zhou C, Lin J, Wang Y, Cui F, Zhou S, Jia M, Ye S, Zhang Q. Phytosomes loaded with mitomycin C-soybean phosphatidylcholine complex developed for drug delivery. Mol Pharm. 2013;10:90\u2013101.","journal-title":"Mol Pharm"},{"key":"442_CR31","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1080\/10717544.2017.1321062","volume":"24","author":"F Yu","year":"2017","unstructured":"Yu F, Ao MT, Zheng X, Li NN, Xia JJ, Li Y, Li DH, Hou ZQ, Qi ZQ, Chen XD. PEG-lipid-PLGA hybrid nanoparticles loaded with berberine-phospholipid complex to facilitate the oral delivery efficiency. Drug Delivery. 2017;24:825\u201333.","journal-title":"Drug Delivery"},{"key":"442_CR32","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1126\/science.275.5301.810","volume":"275","author":"JO Radler","year":"1997","unstructured":"Radler JO, Koltover I, Salditt T, Safinya CR. Structure of DNA-cationic liposome complexes: dNA intercalation in multilamellar membranes in distinct interhelical packing regimes. Science. 1997;275:810\u20134.","journal-title":"Science"},{"key":"442_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.biomaterials.2017.05.025","volume":"138","author":"R Zhang","year":"2017","unstructured":"Zhang R, Song X, Liang C, Yi X, Song G, Chao Y, Yang Y, Yang K, Feng L, Liu Z. Catalase-loaded cisplatin-prodrug-constructed liposomes to overcome tumor hypoxia for enhanced chemo-radiotherapy of cancer. Biomaterials. 2017;138:13\u201321.","journal-title":"Biomaterials"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-019-0442-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12951-019-0442-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-019-0442-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,18]],"date-time":"2020-01-18T19:05:37Z","timestamp":1579374337000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-019-0442-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,19]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["442"],"URL":"https:\/\/doi.org\/10.1186\/s12951-019-0442-x","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,19]]},"assertion":[{"value":"11 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"8"}}